Drug intelligence / Profile preview

SC100

Development stage
Unknown
Lead developer
Genescient
Administration
Oral
01

Overview

SC100 is a proprietary botanical supplement developed by Genescient Corporation, designed to promote life extension and enhance stress resistance. It consists of a complex mixture of herbal extracts that are predicted to modulate the expression of several key genes and pathways involved in the aging process, including the mechanistic target of rapamycin (mTOR), nitric oxide synthase (NOS), nuclear factor kappa B (NF-kappaB), and vascular endothelial growth factor (VEGF). Research conducted in *Drosophila* models has shown that SC100 can stabilize midlife mortality rates and significantly extend maximum lifespan. While it is commercially available as a dietary supplement under the brand name Stem Cell 100, versions of the formulation have also been evaluated in double-blind, placebo-controlled human clinical trials to study its effects on aging and stress resistance.

Brand names
Stem Cell 100
Other names
Genescient SC100
02

Targets

mTOR (Mammalian target of rapamycin kinase)VEGFA (Vascular endothelial growth factor A)NOS1 (nNOS)NF-κB

Beyond the preview

Go deeper on SC100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SC100.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call